Atheromatous disease is the first cause of death and dependency in developed countries and carotid artery atherosclerosis is one of the main causes of severe ischaemic strokes. Current management strategies are mainly based on the degree of stenosis and patient selection has limited accuracy. This information could be complemented by the identification of biomarkers of plaque vulnerability, which would permit patients at greater and lesser risk of stroke to be distinguished, thus enabling a better selection of patients for surgical or intensive medical treatment. Although several circulating protein-based biomarkers with significance for both the diagnosis of carotid artery disease and its prognosis have been identified, at present, none have been clinically implemented. This review focuses especially on the most relevant clinical parameters to take into account in routine clinical practice and summarises the most up-to-date data on epigenetic biomarkers of carotid atherosclerosis and plaque vulnerability.
1 January 2022 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial–mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy.
Inflammation contributes to haematoma expansion (HE) and poor prognosis in spontaneous intracerebral haemorrhage (ICH). This study aimed to characterise the temporal profile of soluble Toll-like receptor 4 (sTLR4) during the hyperacute and acute phases of ICH and to evaluate its association with HE. Serum sTLR4 levels were measured at admission, 24 and 72 h from 99 patients with primary hemispheric ICH within 12 h of symptom onset, and at baseline from 39 non-stroke controls using enzyme-linked immunosorbent assay (ELISA). Longitudinal sTLR4 fluctuations were evaluated through linear mixed-effects models. Independent HE prognosticators were identified using multivariable logistic regression, and model performance was assessed via the area under the receiver operating characteristic curve (AUC-ROC). ICH patients exhibited significantly higher baseline sTLR4 levels than controls, which declined over time and were not associated with clinical variables. Notably, patients with HE demonstrated higher admission sTLR4 levels than those without HE (2.50 [95% CI: 1.84–3.16] vs. 1.62 [95% CI: 1.22–2.02] ng/mL, p = 0.027). Furthermore, while the non-HE group showed a rapid decrease within the first 24 h, the HE group maintained elevated levels with a more gradual decline. A multivariable model incorporating baseline ICH volume and sTLR4 levels achieved an AUC of 0.829, with positive and negative predictive values of 70.8% and 90.1%, respectively. These findings suggest that TLR4 may be involved in the pathophysiology of HE, and the combination of baseline ICH volume and sTLR4 levels could serve as a useful tool to stratify patients into low- and high-risk groups for HE.